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There were no significant differences in the rate of complica-
tions other than vascular complications, which were more
common in women (2.7% vs. 1.0%).
Conclusions: Women are referred for ablation of AF less often
and later than men, and the efficacy of RFCA of AF is
lower in women than men.
Perspective: Women also appear to be under-referred for
diagnostic cardiovascular testing, defibrillator implantation,
and coronary artery bypass grafting. The reason for this gen-
der discrepancy is unclear. The lower efficacy of RFCA in
women may be related to greater atrial remodeling associ-
ated with the longer interval from diagnosis to ablation.  
Summary written by: Fred Morady, MD
Cardiovascular Surgery
Nonsteroidal Anti-Inflammatory Drug Treatment
for Postoperative Pericardial Effusion: A
Multicenter Randomized, Double-Blind Trial
Meurin P, Tabet JY, Thabut G, et al.
Ann Intern Med 2010;152:137–143.
Study Question: Is the nonsteroidal anti-inflammatory drug
(NSAID) diclofenac effective in reducing postoperative
pericardial effusion volume after cardiac surgery?
Methods: A multicenter, randomized, double-blind, placebo-
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Arrhythmias
Outcomes and Complications of Catheter Ablation
for Atrial Fibrillation in Females
Patel D, Mohanty P, Biase L, et al.
Heart Rhythm 2010;7:167–172.
Study Question: Are there gender-based differences in the
results of radiofrequency catheter ablation (RFCA) of atrial
fibrillation (AF)?
Methods: This was a retrospective analysis of 518 women and
2,747 men who underwent RFCA of AF with a 3.5-mm
irrigated-tip ablation catheter. All patients underwent pul-
monary vein antrum isolation, with superior vena cava
isolation and ablation of fractionated atrial electrograms as
clinically indicated. Daily event monitor recordings were
obtained for the first 5 months post-ablation, and a 48-hour
or 7-day Holter monitor was performed at 3- to 6-month
intervals. Efficacy was defined as freedom from AF/atrial
tachycardia in the absence of antiarrhythmic drug therapy
after an 8-week blanking period.
Results: The women were significantly older than the men
(mean age 59 vs. 56 years) and the interval from diagnosis to
referral for RFCA was significantly longer in the women (6.5
vs. 4.8 years). At a mean of 24 months of follow-up, efficacy
was significantly lower in the women (68.5% vs. 77.5%). In
women, higher body mass index, persistent AF, and nonpul-
monary vein triggers were independent predictors of failure.
SCANNING THE LITERATURE
Summaries of Key Journal Articles
Kim A. Eagle, MD, Editor-in-Chief, Journal Scan, Ann Arbor, MI
Christopher P. Cannon, MD, Editor-in-Chief, Cardiosource, Boston, MA
William F. Armstrong, MD, Ann Arbor, MI, David S. Bach, MD, Ann Arbor, MI, Ragavendra R.
Baliga, MBBS, Columbus, OH, Timothy B. Cotts, MD, Ann Arbor, MI, Daniel T. Eitzman, MD, 
Ann Arbor, MI, James B. Froehlich, MD, Ann Arbor, MI, Caren S. Goldberg, MD, Ann Arbor, MI,
Hitinder S. Gurm, MBBS, Ann Arbor, MI, Jennifer C. Hirsch, MD, Ann Arbor, MI, Elizabeth Anne
Jackson, MD, Ann Arbor, MI, Fred Morady, MD, Ann Arbor, MI, Debabrata Mukherjee, MD,
Lexington, KY, Himanshu J. Patel, MD, Ann Arbor, MI, Melvyn Rubenfire, MD, Ann Arbor, MI, 
Gilbert R. Upchurch, Jr., MD, Ann Arbor, MI, Associate Editors, Cardiosource
banding and 18 of the 25 subjects who received supervised
lifestyle modification completed the study. More gastric band-
ing patients lost >50% of excess weight compared to the
lifestyle intervention patients (84% vs. 12%). Mean weight
change in the gastric banding group was 34.6 kg of weight
loss, representing an excess weight loss of 78.8% or 12.7 BMI
units. The mean weight loss in the lifestyle intervention group
was 3.0 kg, representing an excess weight loss of 13.2% or 1.3
BMI units. At the end of the 2-year follow-up, no subjects in
the gastric banding group had the metabolic syndrome, com-
pared to 4 of the 18 completers in the lifestyle group.
Conclusions: Among severely obese adolescents, gastric band-
ing was associated with significant long-term weight loss
and improvement in metabolic syndrome criteria.
Perspective: This study suggests that gastric banding is a poten-
tial therapy for adolescents who require significant weight
loss. Larger-scale studies are warranted, which includes data
on adverse effects after such procedures.  
Summary written by: Elizabeth A. Jackson, MD
General Cardiology
Altitude and the Heart: Is Going High Safe for Your
Cardiac Patient?
Higgins JP, Tuttle T, Higgins JA.
Am Heart J 2010;159:25–32.
Perspective: Acute exposure to high altitude is associated
with significant alterations to the cardiovascular system,
with acute hypoxia, increased myocardial work, increased
epinephrine release, and increased pulmonary artery pres-
sures. This review summarized the physiology and clinical
evidence regarding acute altitude exposure on the cardiopul-
monary system, and made practical recommendations for
patients with cardiovascular disease. Points to remember are: 
1: Environmental changes when moving from sea level to high
altitude include reductions in atmospheric pressure, oxygen
pressure, humidity, and temperature. Significant changes typi-
cally begin at about 2500 m (8200 ft). The effect on patients
depends on the degree of hypoxia, change in elevation, rate of
ascent, level of acclimatization, exercise intensity at altitude,
age, and genetics.
2: Moderate altitude is defined as 1500-2500 m (4950-8250
ft). High altitude is defined as >2500 m (8250 ft).
3: The acute cardiopulmonary effects of altitude include:
• Tissue hypoxia, as a result of the significant decrease in
oxygen availability in inspired air. Pulmonary vascular
resistance increases 50-300%. 
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controlled trial was conducted at five postoperative cardiac
rehabilitation centers. A total of 196 patients with moderate
to large pericardial effusion (grade 2, 3, or 4 on a scale of 0
to 4; measured by echocardiography) persistent more than 7
days after cardiac surgery were randomly assigned treatment
with either diclofenac 50 mg or placebo twice daily for 14
days. Endpoints were change in effusion grade after 14 days
of treatment and frequency of late cardiac tamponade.
Results: The initial mean pericardial effusion grade was 2.6 ±
0.7 in the placebo group and 2.8 ± 0.8 in the diclofenac
group. The two groups showed similar mean decreases from
baseline after treatment (-1.1 ± 1.2 grades for the placebo
group vs. -1.4 ± 1.2 for the diclofenac group). The mean dif-
ference between groups was -0.28 grade (p = 0.105). There
were 11 cases of late cardiac tamponade in the placebo group
and nine in the diclofenac group (p = 0.64). Differences per-
sisted after adjustment for grade of pericardial effusion at
baseline, treatment site, and type of surgery.
Conclusions: In patients with pericardial effusion after cardiac
surgery, the NSAID diclofenac neither reduced the size of
postoperative pericardial effusions nor prevented late cardiac
tamponade.
Perspective: These data, although limited by relative small
sample size, refute the efficacy of the NSAID diclofenac (at
a dose of 60 mg BID) for the treatment of postoperative
pericardial effusion. In light of potential adverse effects
associated with NSAID use, supporting data should be pro-
vided before the routine use of NSAIDs in this scenario.  
Summary written by: David S. Bach, MD
Congenital Heart Disease
Laparoscopic Adjustable Gastric Banding in
Severely Obese Adolescents: A Randomized Trial
O’Brien PE, Sawyer SM, Laurie C, et al.
JAMA 2010;303:519–526.
Study Question: Is gastric banding comparable to optimal
lifestyle intervention for weight loss among severely obese
adolescents?
Methods: This was a prospective randomized controlled trial
of adolescents (ages 14-18 years) comparing supervised
lifestyle intervention or gastric banding. All subjects were
severely obese, with a body mass index (BMI) greater than
35 kg/m2. Follow-up continued for 2 years, with a main
outcome of weight loss. Secondary outcomes included
changes in metabolic syndrome, insulin resistance, quality of
life, and adverse outcomes.
Results: A total of 24 of the 25 subjects who received gastric
encouraged before exercise at altitude. Alcohol consumption
should be minimized, and hydration should be maintained. If
cardiac status is unknown, exercise testing can be considered
prior to travel.  
10: Recommendations for patients with cardiovascular disease.
Patients with unstable cardiac disease should not exercise at
high altitude. Patients with severe cardiac diseases should not
ascend to high altitude. Patients should avoid traveling to
high altitude for 14 days after an acute coronary event.
Patients with stable heart disease should limit physical activity
for the first few days after ascent. Patients should be advised
that they could become symptomatic at lower workloads when
at altitude. Patients with pacemakers can safely travel to high
altitude with no impact on ventricular stimulation thresholds.    
Summary written by: David S. Bach, MD 
Jet Lag
Sack RL.
N Engl J Med 2010;362:440–447.
Perspective: The following are 10 points to remember about
jet lag: 
1: Jet lag is a sleep disorder that results from crossing time
zones too rapidly for the circadian clock to keep pace. The lat-
ter is normally synchronized to the solar light-dark cycle and
promotes alertness during the day and sleep at night. Jet lag is
compounded by travel fatigue, dehydration, and prolonged
immobility.
2: Symptoms of jet lag include insomnia and daytime sleepi-
ness, as well as dysfunction of mood, and physical and
cognitive performance.
3: Melatonin is a hormone secreted for about 10-12 hours at
night and is synchronized to the light-dark cycle by the cir-
cadian clock.
4: For short trips, jet lag can be minimized by maintaining the
home sleep-wake schedule if possible, or alternatively for 2
days prior to the flight, shift the sleep schedule by 1-2 hours
toward the destination time zone.
5: Treatment for jet lag includes appropriate exposure to light,
melatonin, or both; supplement as needed with medication to
counteract insomnia or daytime sleepiness.  
6: Zolpidem 10 mg was more effective than melatonin at
reducing symptoms of jet lag, but is not ideal because of dura-
tion of action. Upon landing in the new time zone, melatonin
0.5-3 mg may be helpful to promote sleep when traveling
west to east.
7: Hypnosedatives need to be used with caution, as they may
further increase the elevated risk for deep vein thrombosis.  
• Initial hyperventilation leads to respiratory alkalosis
that transiently shifts leftward the oxygen-hemoglobin
dissociation curve.
• Heart rate increased at rest.
• A reduction in plasma volume caused by increased res-
piratory, urinary, and cutaneous losses. 
• Parasympathetic nervous system deactivation, with pre-
domination of sympathetic nervous responses. 
• Glycogenolysis stimulated by the increase in epineph-
rine, causing increased use of glucose at rest and with
exercise, and increased blood lactate levels. 
4: Coronary artery disease. The acute physiological changes
associated with high altitude result in earlier onset of ischemia
and symptomatic angina in patients with coronary artery dis-
ease, and at a lower pressure-rate product.
5: Heart failure. Increased sympathetic activity results in vaso-
constriction and tachycardia, as well as release of inflammatory
mediators. Increased sympathetic activity results in increased
heart rate and systemic vascular resistance. Pulmonary vaso-
constriction leads to pulmonary hypertension, probably the
most significant factor in reducing cardiopulmonary perform-
ance at altitude in patients with heart failure.  
6: High altitude pulmonary edema. High-altitude (noncardio-
genic) pulmonary edema affects unacclimatized people with a
genetic predisposition, typically within 4 days of arriving at
altitude. 
• Slow ascent serves as a preventative measure. (For ascent
>3050 m [10,000 ft], ascent should be ≤305 m [1000 ft]
daily with a rest every 1000 m [3300 ft].) 
• If suspected, immediate descent and administration of
supplemental oxygen is the treatment of choice. 
• Nifedipine (sustained release 20-30 mg orally q 6 to 12
h) can both prevent and treat high-altitude pulmonary
edema. 
• Tadalafil 10 mg bid or sildenafil 50 mg q 8h can be used
to prevent high-altitude pulmonary edema, but treat-
ment doses have not been established.
7: Arrhythmia. Increased sympathetic activity associated with
high altitude can increase the frequency and duration of
supraventricular and ventricular arrhythmias with or without
underlying heart disease.  
8: Congenital heart disease. In simple uncomplicated congenital
heart disease, arterial oxygen desaturation can occur at high
altitude when the usual left-to-right shunting of blood
reverses, owing to increased right-sided pressures.  
9: Recommendations for all people. Limit activity to a lower
maximal level than at sea level. Raise sleeping altitude gradu-
ally. At least moderate physical conditioning at sea level is
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8: A short-acting sleeping pill during the flight is preferred,
such as zaleplon 5-10 mg. Sedatives should not be combined
with alcohol.  
9: Prior to and during the trip, hydration will help as well as
avoiding caffeine for several hours prior to sleep time. When
traveling east to west, seek bright sunlight in the evening; for
west to east, seek bright sun in the morning.  
10: Increased consumption of caffeine may counteract daytime
sleepiness. This needs to be weighed against possible increase
in insomnia.    
Summary written by: Melvyn Rubenfire, MD 
Dose of Prophylactic Platelet Transfusions and
Prevention of Hemorrhage
Slichter SJ, Kaufman RM, Assmann SF, et al.
N Engl J Med 2010;362:600–613.
Study Question: What is the effect of platelet dose on bleeding
in patients with hypoproliferative thrombocytopenia?
Methods: The investigators randomly assigned hospitalized
patients undergoing hematopoietic stem-cell transplanta-
tions or chemotherapy for hematologic cancers or solid
tumors to receive prophylactic platelet transfusions at a low,
medium, or high dose (1.1 x 1011, 2.2 x 1011, or 4.4 x 1011,
platelets per square meter of body-surface area, respectively)
when morning platelet counts were 10,000 per cubic mil-
limeter or lower. Clinical signs of bleeding were assessed
daily. The primary endpoint was bleeding of grade 2 or
higher (as defined by World Health Organization criteria).
Results: In the 1,272 patients who received at least one
platelet transfusion, the primary endpoint was observed in
71%, 69%, and 70% of the patients in the low-, medium-,
and high-dose group, respectively (differences were non-
significant). The incidences of higher grades of bleeding
and other adverse events were similar among the three
groups. The median number of platelets transfused was sig-
nificantly lower in the low-dose group (9.25 x 1011) than in
the medium- (11.25 x 1011) or high-dose group (19.63 x
1011), but the median number of platelet transfusions given
was significantly higher in the low-dose group (five, vs.
three each in the medium- and high-dose groups).
Conclusions: At doses between 1.1 x 1011 and 4.4 x 1011
platelets per square meter, the number of platelets in the
prophylactic transfusion has no effect on the incidence of
bleeding.
Perspective: Overall, the data suggest that when prophylactic
transfusions are administered after a trigger threshold dose
of 10,000 platelets/cubic millimeter is reached, dose has no
effect on bleeding. A strategy of low-dose transfusion may
therefore significantly reduce the quantity of transfused
platelets, preserving scarce blood components. However, this
may increase the total number of platelet transfusions.
Additional studies to determine optimal dose and frequency
of platelet transfusions are indicated.  
Summary written by: Debabrata Mukherjee, MD
Arterial Stiffness and Cardiovascular Events: 
The Framingham Heart Study 
Mitchell GF, Hwang SJ, Vasan RS, et al.
Circulation 2010;121:505–511.
Study Question: Are measures of arterial stiffness and wave reflec-
tion markers of risk and prognosis in the community setting?
Methods: A proportional hazards model was used to analyze
first-onset major cardiovascular disease (CVD) events
(myocardial infarction, unstable angina, heart failure, or
stroke) in relation to arterial stiffness (pulse wave velocity
[PWV]), wave reflection (augmentation index, carotid-
brachial pressure amplification), and central pulse pressure in
2,232 participants (mean age, 63 years; 58% women) in the
Framingham Heart Study. The primary goal was to deter-
mine whether arterial stiffness predicted CVD events after
adjustment for standard CVD risk factors.
Results: During median follow-up of 7.8 years, 151 of 2,232
participants (6.8%) experienced an event. In multivariable mod-
els adjusted for age, sex, systolic blood pressure, use of
antihypertensive therapy, total and HDL cholesterol, smoking,
and presence of diabetes mellitus, higher aortic PWV was asso-
ciated with a 48% increase in CVD risk (p = 0.002). After
PWV was added to a standard risk factor model, integrated
discrimination improvement was 0.7% (p < 0.05). In contrast,
augmentation index, central pulse pressure, and pulse pressure
amplification were not related to CVD outcomes in multivari-
able models.
Conclusions: Higher aortic stiffness assessed by PWV is associ-
ated with increased risk for a first CV event. Aortic PWV
improves risk prediction when added to standard risk factors,
and may represent a valuable biomarker of CVD risk.
Perspective: Tools are available for clinical use to assess PWV;
however, the clinical utility of PWV for an individual patient
is limited, and this observational study does not establish a
causal relationship between PWV and CVD events. More
importantly, it does lend support for the development of
novel therapies that target aortic stiffness, which can be tested
in clinical trials.  
Summary written by: Melvyn Rubenfire, MD
Methods: The participants were from a community-based
cohort study comprised of 920,985 adults who had at least
one outpatient serum creatinine measurement and who did
not require renal replacement treatment at baseline.
Proteinuria was assessed by urine dipstick or albumin-creati-
nine ratio (ACR). All-cause mortality, myocardial
infarction, and progression to kidney failure were the main
outcome measures.
Results: A majority of individuals (89.1%) had an estimated
GFR (eGFR) of ≥60 ml/min/1.73 m2. Over a median follow-
up of 35 months, 3% of the participants (n = 27,959) died.
The fully adjusted rate of all-cause mortality was higher in
study participants with lower eGFRs or heavier proteinuria.
Adjusted mortality rates were more than twofold higher
among individuals with heavy proteinuria measured by urine
dipstick and eGFR of ≥60 ml/min/1.73 m2, as compared with
those with eGFR of 45-59.9 ml/min/1.73 m2 and normal pro-
tein excretion (rate, 7.2 vs. 2.9 per 1,000 person-years,
respectively). Similar results were observed when proteinuria
was measured by ACR (15.9 and 7.0 per 1,000 person-years
for heavy and absent proteinuria, respectively) and for the out-
comes of hospitalization with acute myocardial infarction,
end-stage renal disease, and doubling of serum creatinine level.
Conclusions: Risks of mortality, myocardial infarction, and
progression to kidney failure associated with a given level of
eGFR are independently increased in patients with higher
levels of proteinuria.
Perspective: Proteinuria and eGFR are two ‘independent’ indi-
cators of renal disease, and this study suggests that when both
are abnormal, poorer outcomes are more likely to occur. The
CHARM study suggested that proteinuria (spot urinary
ACR) is an important prognostic predictor in patients with
heart failure (Lancet 2009;374:543–550). Clearly the next step
is to prevent target-organ damage, particularly prevention and
control of diabetes and hypertension.  
Summary written by: Ragavendra R. Baliga, M.B.B.S.
Interventional Cardiology
Comparison of Ticagrelor With Clopidogrel in
Patients With a Planned Invasive Strategy for
Acute Coronary Syndromes (PLATO): 
A Randomised Double-Blind Study
Cannon CP, Harrington RA, James S, et al., on behalf of the PLATelet
inhibition and patient Outcomes (PLATO) Investigators.
Lancet 2010;375:283–293.
Study Question: What is the relative efficacy and safety of tica-
grelor compared with clopidogrel in patients undergoing an
Association Between 9p21 Genomic Markers and
Heart Disease: A Meta-Analysis
Palomaki GE, Melillo S, Bradley LA.
JAMA 2010;303:648–656.
Study Question: How strong is the association between genetic
variation on chromosome 9p21 and coronary heart disease?
Methods: English-language articles that tested for 9p21 sin-
gle-nucleotide polymorphisms (SNPs) with coronary
heart/artery disease or myocardial infarction as primary out-
comes were included. Articles also provided race, number of
participants, and data to compute an odds ratio (OR). Two
independent reviewers performed data extraction.
Results: Forty-seven data sets from the 22 articles included
were analyzed, including 35,872 cases and 95,837 controls.
The summary OR for heart disease among individuals with
two versus one at-risk allele was 1.25. Age at disease diagno-
sis was a significant covariate, with ORs of 1.35 for age 55
years or younger, and 1.21 for age 75 years or younger. For a
65-year-old man, the 10-year heart disease risk for two versus
one at-risk allele would be 13.2% versus 11%. For a 40-year-
old woman, the 10-year heart disease risk for two versus one
at-risk allele would be 2.4% versus 2.0%. Nearly identical
results were found when comparing one versus zero at-risk
alleles. Three studies showed net reclassification indexes
ranging from −0.1% to 4.8%.
Conclusions: A statistically significant association between
9p21 SNPs and heart disease was found that varied by age at
disease onset, but the magnitude of the association was small.
Perspective: Several studies have shown that SNPs in an
intergenic region of 9p21 are associated with coronary artery
disease. The magnitude of this association and the clinical
utility of this genetic marker for risk stratification are con-
troversial. The current meta-analysis casts doubt on use of
these SNPs for practical management of patients, as this
information is unlikely to affect treatment decisions.  
Summary written by: Daniel T. Eitzman, MD
Relation Between Kidney Function, Proteinuria,
and Adverse Outcomes 
Hemmelgarn BR, Manns BJ, Lloyd A, et al., on behalf of the Alberta
Kidney Disease Network.
JAMA 2010;303:423–429. 
Study Question: What is the association between reduced
glomerular filtration rate (GFR), proteinuria, and adverse
clinical outcome?
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early invasive approach for acute coronary syndromes (ACS)?
Methods: The authors reported the outcome of 13,408 patients
treated with a planned invasive strategy for an ACS and
enrolled in the PLATO trial. Patients were randomly assigned
to ticagrelor and placebo (180 mg loading dose followed by 90
mg twice a day), or to clopidogrel and placebo (300-600 mg
loading dose or continuation with maintenance dose followed
by 75 mg per day) for 6-12 months. All patients were also
treated with aspirin. The primary composite endpoint was
cardiovascular death, myocardial infarction (MI), or stroke.
Results: Percutaneous coronary intervention was performed in
76.8% of the cohort and coronary artery bypass grafting in
5.8%. The primary composite endpoint at 1 year was less fre-
quent in the ticagrelor compared with the clopidogrel group
(9.0% vs. 10.7%; p = 0.0025). There was no difference
between clopidogrel and ticagrelor groups in the rates of total
major bleeding (11.6% vs. 11.5%, p = 0.8803) or GUSTO
severe bleeding (3.2% vs. 2.9%, p = 0.3785). All-cause mortal-
ity was lower with ticagrelor (3.9% vs. 5.0%, p = 0.0103).
Conclusions: Ticagrelor seems preferable to clopidogrel for
patients with ACS, for whom an early invasive strategy is
planned.
Perspective: Ticagrelor is a more potent platelet inhibitor
compared with clopidogrel, and has demonstrated a reduc-
tion in ischemic events with no increase in bleeding over
contemporary therapy. While the reduction in mortality may
be a chance finding, the trends in both MI and death favor
ticagrelor. This drug may displace the use of thienopyridines
in patients with ACS.  
Summary written by: Hitinder S. Gurm, MBBS
Comparison of Platelet Function Tests in
Predicting Clinical Outcome in Patients
Undergoing Coronary Stent Implantation 
Breet NJ, van Werkum JW, Bouman HJ, et al.
JAMA 2010;303:754–762. 
Study Question: Can platelet function tests performed at time of
percutaneous coronary intervention (PCI) predict clinical out-
come?
Methods: The authors prospectively studied 1,069 consecutive
patients that underwent elective stent-based PCI at their
institution between December 2005 and December 2007. All
patients were on clopidogrel, and on-treatment platelet reac-
tivity was measured using light transmittance aggregometry,
VerifyNow P2Y12 assay, Plateletworks assay, IMPACT-R,
and the platelet function analysis system (PFA-100). The pri-
mary endpoint was a composite of all-cause death, nonfatal
acute myocardial infarction, stent thrombosis, and ischemic
stroke. The primary safety endpoint included TIMI major
and minor bleeding.
Results: Adherence to clopidogrel was 95% after 6 months
and 82% at 1 year. Over 1-year follow-up, there were 18
deaths (1.7%), 6.0% had nonfatal acute myocardial infarc-
tion, 1.2% presented with definite stent thrombosis, and
1.3% had a nonfatal ischemic stroke. There were three pos-
sible stent thromboses (0.3%), and bleeding events occurred
in 5.1% of the patients (TIMI-major 3.1%, TIMI-minor
bleeding 2.2%).The primary endpoint occurred more fre-
quently in patients with high on-treatment platelet reactivity
when assessed by light transmittance aggregometry (11.7%
vs. 6.0%), VerifyNow (13.3% vs. 5.7%), and Plateletworks
(12.6% vs. 6.1%). None of the tests identified patients at risk
for bleeding.
Conclusions: Assessment of platelet function using light trans-
mittance aggregometry, VerifyNow, and Plateletworks was
significantly but modestly associated with ischemic events at
1 year.
Perspective: Multiple studies have established an association
between a lesser degree of platelet inhibition and the occur-
rence of atherothrombotic events. The field has been
clouded by the use of multiple platelet function assays with
little inter-assay correlation. This study, with its large popu-
lation and nearly 100% follow-up, provides much needed
clarity to the field. Given the moderate strength of the asso-
ciation between three assays, it would be premature to use
platelet function testing to guide routine clinical practice.  
Summary written by: Hitinder S. Gurm, MBBS
Second-Generation Everolimus-Eluting and
Paclitaxel-Eluting Stents in Real-Life Practice
(COMPARE): A Randomised Trial
Kedhi E, Joesoef KS, McFadden E, et al.
Lancet 2010;375:201–209.
Study Question: What is the safety and efficacy of the second-
generation everolimus-eluting stent (EES) and
paclitaxel-eluting stents (PES) in real-life practice?
Methods: The authors randomized 1,800 consecutive patients
(ages 18-85 years) undergoing percutaneous coronary inter-
vention (PCI) at their center to treatment with EES or PES
in a single-blind fashion. Primary endpoint was a composite of
all-cause mortality, myocardial infarction, and target vessel
revascularization within 12 months.
Results: The primary endpoint occurred less frequently with
the EES compared with the PES (6% vs. 9%, p = 0.02).
This difference was driven by a lower risk of stent thrombo-
sis (0.7% vs. 3%, p = 0.002), myocardial infarction (3% vs.
5%, p = 0.007), and target vessel revascularization (2% vs.
6%; p = 0.0001). There was no difference in all-cause mor-
tality (2% vs. 2%) or cardiac mortality (1% vs. 1%).
Conclusions: The EES was superior to PES in patients
undergoing contemporary PCI.
Perspective: The results of this study corroborate those of the
recently presented SPIRIT IV trial, suggesting that the EES
is superior to PES. Interestingly, there was no difference in
outcome with the two stents in diabetic patients in the two
trials. However, neither trial was powered specifically for this
subset; thus, EES should be preferentially used over PES in
both diabetic and nondiabetic patients undergoing PCI.  
Summary written by: Hitinder S. Gurm, MBBS 
Impact of Femoral Vascular Closure Devices and
Antithrombotic Therapy on Access Site Bleeding in
Acute Coronary Syndromes: The Acute
Catheterization and Urgent Intervention Triage
Strategy (ACUITY) Trial
Sanborn TA, Ebrahimi R, Manoukian SV, et al.
Circ Cardiovasc Interv 2010;3:57–62.
Study Question: What is the impact of vascular closure devices
(VCDs) on access site bleeding in patients undergoing an
early invasive approach for acute coronary syndromes (ACS)
and coronary angiography using femoral arterial access?
Methods: The authors assessed the impact of VCD use on
access site bleeding (ASB) among 11,621 patients undergoing
femoral angiography in the ACUITY trial. The ACUITY
trial randomized patients with ACS to receive heparin
(unfractionated or enoxaparin) plus glycoprotein IIb/IIIa
inhibitor (GPI), bivalirudin plus GPI, or bivalirudin
monotherapy in an open-label fashion.
Results: A VCD was used in 4,307 (37.1%) patients, and
7,314 (62.9%) had manual compression. The rate of ASB
was lower in patients treated with VCD (2.5% vs. 3.3%; p =
0.01). Rates of bleeding were lowest in patients treated with
bivalirudin monotherapy and a VCD (0.7%). After adjusting
for differences in baseline variables, both VCD use (p =
0.04) and bivalirudin monotherapy (p < 0.0001) were inde-
pendently associated with freedom from ASB.
Conclusions: Use of VCD was associated with a reduced rate of
ASB in patients with ACS undergoing an early invasive
approach.
Perspective: No large well-designed randomized trials support
reduction in bleeding events with VCDs. Prior meta-analyses
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suggest worse outcome with VCDs, whereas observational
studies suggest better outcomes with VCDs. It is not clear
whether the findings of the current study reflect inability to
adjust for confounding or are truly reflective of better out-
comes with VCDs. The most effective strategy for reducing
ASB complications is radial access, and this strategy should
be considered in all patients at risk for ASB.  
Summary written by: Hitinder S. Gurm, MBBS 
Noninvasive Cardiology
Physical Activity and Physiological Cardiac
Remodelling in a Community Setting: 
The Multi-Ethnic Study of Atherosclerosis (MESA)
Turkbey EB, Jorgensen NW, Johnson WC, et al.
Heart 2010;96:42–48.
Study Question: Is there an association between physical activ-
ity and left ventricular (LV) structure and function in the
general population in a community setting?
Methods: Subjects included 4,992 multiethnic participants (age
45-84 years; 52% women) free of clinically apparent cardio-
vascular disease enrolled in a cross-sectional population-based
study of subclinical atherosclerosis (MESA). LV mass, vol-
umes, and function were assessed by cardiac magnetic
resonance imaging. Physical activity, defined as intentional
exercise and total moderate and vigorous physical activity,
was assessed by a standard semi-quantitative questionnaire.
Results: LV mass and end-diastolic volume were positively
associated with physical activity (1.4 g/m2 [women] and 3.1
g/m2 [men] greater LV mass in the highest category of
intentional exercise compared with individuals reporting no
intentional exercise; p = 0.05 and p < 0.001, respectively).
Relationships were nonlinear, with stronger positive associ-
ations at lower levels of physical activity (test for
nonlinearity; p = 0.02 and p = 0.03, respectively). Cardiac
output and ejection fraction were unchanged with increased
physical activity levels. Resting heart rate was lower in
women and men with higher physical activity levels (22.6
bpm; p < 0.001).
Conclusions: In a community-based population free of appar-
ent cardiovascular disease, higher physical activity levels were
associated with proportionally greater LV mass and end-dias-
tolic volume and lower resting heart rate.
Perspective: This study reveals that, among active individuals
not trained as elite athletes, higher levels of physical activity
are associated with cardiac changes similar to those seen with
more intense training. Importantly, increased LV mass, asso-
ciated with increased cardiovascular risk among patients with
hypertension, appears benign (or beneficial) when it is
acquired with physical activity. An increased LV mass, in
other scenarios, would raise concern.  
Summary written by: David S. Bach, MD
Prevention/Vascular
Statins and Risk of Incident Diabetes: 
A Collaborative Meta-Analysis of Randomised 
Statin Trials
Sattar N, Preiss D, Murray HM, et al. 
Lancet 2010;Feb 17:[Epub ahead of print].
Study Question: Is there a relationship between statin use and
development of diabetes?
Methods: The authors conducted a MEDLINE, Embase, and
the Cochrane Central Register of Controlled Trials search,
from 1994–2009, for randomized controlled endpoint trials of
statins. Trials included had more than 1,000 patients, with
identical follow-up in every group, and duration of more than
1 year. Trials were excluded if they involved organ transplant
or hemodialysis. Calculated risk estimates for incident diabetes
were performed with a random-effect meta-analysis.
Results: Thirteen statin trials with 91,140 participants were
identified, of whom 4,278 (2,226 assigned statins and 2,052
assigned control therapy) developed diabetes during a mean
4 years. Statin therapy was associated with a 9% increased
risk for incident diabetes, with little heterogeneity (I2 =
11%) between trials. Meta-regression showed that risk of
development of diabetes with statins was highest in trials
with older participants, but neither baseline body mass
index nor change in low-density lipoprotein cholesterol
accounted for residual variation in risk. Treatment of 255
patients with statins for 4 years resulted in one extra case of
diabetes.
Conclusions: Statin therapy is associated with a slightly
increased risk of development of diabetes, but the risk is low
both in absolute terms and when compared with the reduction
in coronary events.
Perspective: The findings are of interest, but should have no
impact on clinical practice. The lay literature has waved a
flag of concern about statins inducing diabetes. But the
modest 9% increase in diabetes is more than balanced by the
benefits of statins in diabetics and nondiabetics alike. In the
present meta-analysis, there was no difference between
water-soluble and fat-soluble statins.  
Summary written by: Melvyn Rubenfire, MD
Effectiveness of Extended-Duration Transdermal
Nicotine Therapy: A Randomized Trial
Schnoll RA, Patterson F, Wileyto EP, et al.
Ann Intern Med 2010;152:144–151.
Study Question: Does extended nicotine therapy improve
abstinence from tobacco?
Methods: This randomized controlled trial compared
extended-duration nicotine replacement (24 weeks), standard-
duration nicotine replacement (8 weeks), and placebo (16
weeks) for abstinence from tobacco. Participants were blinded
to assignment. Subjects were eligible if they sought treatment
for smoking from October 2004 to March 2008, were age 18-
65 years, smoked 10 or more cigarettes per day for the past
year or more, and had no comorbid conditions such as heart
attack or stroke within the prior 6 months. Abstinence from
tobacco was confirmed by carbon monoxide levels at weeks 24
and 52. Secondary outcome measures included quitting char-
acteristics such as lapses, relapse, and recover events.
Results: A total of 568 adult smokers were included. At 24
weeks, subjects randomized to extended-duration nicotine
replacement had higher rates of point-prevalence abstinence
compared to standard-duration therapy (31.6% vs. 20.3%).
Similar patterns were noted for prolonged abstinences
(41.5% vs. 26.9%) and continuous abstinence (19.2% vs.
12.6%). Extended-duration therapy also reduced risk for
lapse and improved chances for recovery after a lapse. At 52
weeks, extended-duration therapy was associated with
higher quit rates for prolonged abstinence. Time to relapse
was longer among those randomized to extended-duration
therapy compared to those on standard-duration therapy.
Conclusions: Extended-duration nicotine therapy increased
continuous abstinence at 24 weeks, with lower lapses and
increased recovery after a lapse.
Perspective: Further study is warranted regarding the use of
extended duration of nicotine therapy for smokers, includ-
ing research in other populations such as those with heart
disease, prior to widespread acceptance of extended-dura-
tion therapy. However, these data suggest the potential
benefit for nicotine replacement beyond 8 weeks in many
smokers.  
Summary written by: Elizabeth A. Jackson, MD
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